Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment

Medical Mycology

Volumn 46, Issue 3, 2008, Pages 259-263

  Speletas, Matthaios ^a,b   Vyzantiadis, Timoleon Achilleas ^c   Kalala, Fani ^a   Plastiras, Dimitrios ^a   Kokoviadou, Kyriaki ^b   Antoniadis, Antonios ^c   Korantzis, Ioannis ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Candida glabrata; Candida krusei; Chronic myeloid leukemia (CML); Imatinib; TLR

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; ERYTHROPOIETIN; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HYDROXYUREA; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

AGED; ARTICLE; CANDIDA GLABRATA; CANDIDA KRUSEI; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE PREDISPOSITION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FATALITY; FEVER; GENETIC POLYMORPHISM; HUMAN; INFECTIOUS PNEUMONIA; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LUNG MYCOSIS; LYMPHOCYTE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; NEUTROPHIL; OPPORTUNISTIC INFECTION; PANCYTOPENIA; THROMBOCYTE COUNT; TREATMENT DURATION; CANDIDA; CANDIDIASIS; GENETICS; ISOLATION AND PURIFICATION; LUNG; MICROBIOLOGY; MYELOID LEUKEMIA; PNEUMONIA; RADIOGRAPHY;

CANDIDA; CANDIDA GLABRATA; ISSATCHENKIA ORIENTALIS;

AGED; CANDIDA; CANDIDIASIS; HUMANS; LEUKEMIA, MYELOID; LUNG; MALE; OPPORTUNISTIC INFECTIONS; PIPERAZINES; PNEUMONIA; POLYMORPHISM, GENETIC; PYRIMIDINES; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 47249105036     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780701558969     Document Type: Article

References (17)

1. Deininger, M., Buchdunger, E. and Druker, BJ. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105, pp. 2640-2653.
2. Dietz, AB, Souan, L. and Knutson, GJ (2004) Imatinib inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood, 104, pp. 1094-1149.
3. Cwynarski, K., Laylor, R. and Macchiarulo, E. (2004) Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia, 18, pp. 1332-1339.
4. Mattiuzzi, G., Cortes, JE and Talpaz, M. (2003) Development of varicella-zoster virus infection in patients with chronic myeloid leukemia treated with imatinib mesylate. Clin Cancer Res, 9, pp. 976-980.
5. Bekkenk, MW, Vermeer, MH and Meijer, JLM (2003) EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood, 102, p. 4243.
6. Lin, JT, Lee, MY and Hsiao, LT (2004) Pulmonary nocardiosis in a patient with CML relapse undergoing imatinib therapy after bone marrow transplantation. Ann Hematol, 83, pp. 444-446.
7. Kullberg, BJ and Lashof, AML. Oude (2002) Epidemiology of opportunistic invasive mucoses. Eur J Med Res, 7, pp. 183-191.
8. Boktour, MR, Kontoyiannis, DP and Hanna, HA (2004) Multiple-species candidemia in patients with cancer. Cancer, 101, pp. 1860-1865.
9. Petrocheilou-Paschou, V., Georgilis, K. and Kontoyannis, D. (2002) Pneumonia due to Candida krusei. Clin Microbiol Infect, 8, pp. 806-809.
10. Lorenz, E., Frees, KL and Schwartz, DA. (2001) Determination of the TLR4 genotype using allele-specific PCR. Biol Blood Marrow Transplant, 31, pp. 22-24.
11. Ogus, AC, Yoldas, B. and Ozdemir, T. (2004) The Arg753Gln polymorphism of the human Toll-like receptor 2 gene in tuberculosis disease. Eur Respir J, 23, pp. 219-223.
12. Lokeshwar, N., Kumar, L. and Kumari, M. (2005) Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myeloid leukemia. Leuk Lymphoma, 46, pp. 781-784.
13. Gambillara, E., Laffitte, E. and Widmer, N. (2005) Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology, 211, pp. 363-365.
14. Selleslag, D. (2006) A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta Biomed, 77, pp. 32-35.
15. Netea, MG, Van der Graaf, C., Van der Meer, JWM and Kullberg, BJ. (2004) Recognition of fungal pathogens by Toll-like receptors. Eur J Clin Microbiol Infect Dis, 23, pp. 672-676.
16. Roeder, A., Kirschning, CJ and Rupec, RA (2004) Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol, 42, pp. 485-498.
17. Van der Graaf, CA, Netea, MG and Morre, SA (2006) Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw, 17, pp. 29-34.